We have previously shown that VCAM-1 expression is induced on human umbilical vein EC (HUVEC) by both tumor necrosis factor a (TNFa) and interleukin-la (IL-la), whereas on human dermal microvascular EC (HDMEC) only TNFa results in VCAM-1 expression. To explore molecular mechanisms responsible for these contrasting patterns of VCAM-1 induction in HUVEC versus HDMEC, we performed transcriptional activation studies with VCAM-1 -based reporter constructs and in vitro binding assays using two adjacent NF-KB binding sequences of the VCAM-1 promoter as a DNA probe. Previous studies DHESION of white blood cells to the microvasculature represents an important step in the initial inflammatory response within any tissue. The attachment of leukocytes to endothelium is based on the precise interplay of cell adhesion receptors, chemoattractants, and cytokines, all of which provide distinct signals to control leukocyte traffi~."~ The regulated expression of vascular cell adhesion molecule-l (VCAM-1) on endothelial cells (EC) is an important component of this process." VCAM-1 belongs to the immunoglobulin gene superfamily of adhesion receptors, and is induced on human EC by a variety of proinflammatory ~ytokines.~ VCAM-1 preferentially mediates adhesion to mononuclear leukocytes through interaction with the integrin receptor a4pI (VLA-4), which is expressed on lymphocytes, monocytes, and eosinophils, but not on neutrophik6
DHESION of white blood cells to the microvasculature
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Leukocyte-endothelial cell interactions have primarily been examined on large vessel-derived human umbilical vein EC (HUVEC). However, studies on human dermal microvascular EC (HDMEC) have demonstrated distinct differences from large-vessel EC with regard to growth requirements in vitro,7 immunologic phenotypes,8 and regulation of cell adhesion protein^.^^'" Since the vast majority of endothelial cell-leukocyte interactions occur in the microvasculature, regulation of critical adhesion proteins on small vesselderived EC substantially influences the localization of leukocytes at sites of inflammation.
One specific difference, which we have previously demonstrated, concerns induction and expression of VCAM-1 in response to tumor necrosis factor a (TNFa) and interleukinla (IL-la)." VCA"1 cell-surface and mRNA expression are induced by both IL-la and TNFa in HUVEC. However, in HDMEC, only TNFa leads to VCAM-1 expression. This differential regulation is not due to the lack of IL-la responsiveness in HDMEC, because IL-la induces expression of both intercellular adhesion molecule-l (ICAM-1) and E-selectin in a time-and concentration-dependent manner in this endothelial cell type."." Since this difference in VCAM-1 induction is reflected at steady-state mRNA levels, and since nuclear run-off transcription assays have previously identified newly transcribed VCAM-1 mRNA in response to cytokines," we proposed that this cell-specific lack of IL-la responsiveness was transcriptionally mediated. The purpose of our studies therefore was to explore whether molecular mechanisms could be identified by which VCAM-1 gene transcription is differentially regulated in response to TNFa and IL-la in HUVEC versus HDMEC.
The 5'-transcriptional regulatory region of the human VCAM-1 gene has been recently cloned and characteri~ed.'*,'~ Sequence analysis has revealed two adjacent NF-KB-like binding sites within the first 77 bp of the VCAM-1 promoter. NF-KB proteins are inducible transcription factors central to the regulated expression of numerous immune response Previous studies have established that the tandem W -K B sites of the VCAM-1 promoter are required for cytokine-induced VCAM-1 transcription.'2." In addition, these motifs have been implicated in cell-specific VCAM-1 gene activation by cyt~kines,'~.'~.'~ suggesting that NF-KB may also play a role in the differential VCAM-1 gene transcription in response to TNFa and IL-la in HU-VEC versus HDMEC.
To determine whether the differential VCAM-1 expression is regulated transcriptionally and to further test the hypothesis that NF-KB may be involved in this regulation, we performed transcriptional activation studies with VCAM-1-based reporter constructs and in vitro binding assays using specific sequences of the VCAM-l promoter as a DNA probe. The findings reported here demonstrate a significant HDMEC-specific attenuation of VCAM-1 gene transcription 212 GILLE ET AL in response to IL-la, but not TNFa. An upstream inhibitory element distinct from the NF-KB sites was identified in the VCAM-1 gene regulatory region, which conveys IL-ladependent but not TNFa-dependent inhibition of transcription driven by a heterologous cytokine response element and promoter. These observations provide direct support for cellspecific and cytokine-selective VCAM-1 gene transcription, which may, at least in part, be responsible for the differential VCAM-1 cell-surface induction.
MATERIALS AND METHODS
Isolation and culture of HDMEC. HDMEC were isolated from neonatal foreskins as previously described.' Cells were cultured in HDMEC media consisting of MCDB 131 (Gibco BRL, Grand Island, NY), 30% normal human serum (Irvine Scientific, Santa Ana, CA), epidermal growth factor (5 ng/mL; Clonetics Corp, San Diego, CA), hydrocortisone acetate (1 pg/mL; Sigma Chemical CO, St Louis, MO), dibutyryl cyclic adenosine monophosphate (5 X mol& Sigma), 2 mmol/L glutamine (Irvine), 100 U/mL penicillin (Irvine), 100 pg/mL streptomycin (Irvine), and 250 pg/mL amphotericin B (Irvine). Cells were characterized and purity of cultures was ensured through morphologic appearance, staining for von Willebrand factor (factor VIII-associated antigen), and uptake of acetylated low-density lipoprotein. Experiments were conducted with cells in passages 3 to 5.
Isolation and culture of HUVEC. HUVEC were isolated from collagenase-treated umbilical vein as previously described." Cells were cultured in HUVEC media consisting of medium 199 (Irvine) with 20% fetal bovine serum (Hyclone, Logan, UT), EC mitogen (50 pg/mL; Biomedical Technologies Inc, Stoughton, MA), heparin (12 U/mL; Elkins-Sinn Inc, Cherry Hill, NJ), 2 mmol/L glutamine, 100 U/mL penicillin, 100 pg/mL streptomycin, and 250 pg/mL amphotericin B (Irvine). Cells were used up to passage 5. We have previously established that differences in IL-la responsiveness in HUVEC versus HDMEC are not in any way secondary to differing culture conditions."
Cytokines. Human recombinant IL-la was obtained from Dr Ira Green (National Institutes of Health, Bethesda, MD). Human recombinant TNFa was a generous gift from Genentech Corp (South San Francisco, CA).
Reporter gene constructs and expression vectors. The -933/ +20-bp and the -288/+20-bp VCAM-I CAT constructs were generously provided by Dr Douglas C. Dean (Washington University, St Louis, MO) and have been previously described." Briefly, different portions of the 5'-regulatory region were cloned into the promoterless vector, pBluescriptSKII+ (Stratagene, La Jolla, CA), in which the CAT gene coding region was inserted immediately downstream between a Pstl and a BamHI restriction enzyme site. The -770/+20-bp and -629/+20-bp VCA"1 CAT constructs were synthesized by a polymerase chain reaction technique amplifying the corresponding sequences of the VCAM-1 promoter. Flanking Xho I and Pst I sites facilitated directional cloning into the parent vector. The ICAM-NFKB TK CAT plasmid was constructed by inserting a -199/-172-bp fragment of the ICAM-1 promoter immediately upstream of a minimal thymidine kinase promoter of the pBRAMScat2 vector," which contains the CAT gene downstream of the herpes simplex virus minimal TK promoter. The ICA"1 promoter sequence contains a functional NF-KB binding motif, which has been previously shown to mediate transactivation of heterologous promoters in re- Rosen (Roche Institute of Molecular Biology, Nutley, NJ) and have been previously described." The corresponding cDNAs were cloned between a cytomegalovirus promoter-P-globin intron and SV 40 poly(A) signal.
Transient transfection of reporter gene constructs and analysis oj CAT expression. Forty-eight hours before transfection, HUVEC were plated at densities that produced 60% to 80% confluence in IO-cm tissue culture dishes. Cells were then transfected with 20 pg of appropriate reporter and control plasmids (parent vector) in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum using standard calcium phosphate precipitation techniques." Four hours after transfection, cells were rinsed with Hanks' balanced salt solution and replenished with HUVEC media. Fiftytwo hours after transfection, control transfectants were left untreated (media change) and test transfectants received either 500 U/mL TNFa or 500 U/mL IL-la for 16 hours. Cells were then harvested, and lysates were prepared by rapid freezekhaw cycles. HDMEC were plated 24 hours before transfection at densities that produced 40% to 60% confluence in 10-cm tissue culture dishes. Cells were transfected with 20 pg of appropriate reporter and control plasmids by a modified calcium phosphate method adjusting the pH to 6.95 and culturing the cells at CO, 3.0% and 35°C. Sixteen hours after transfection, cells were rinsed with Hanks' balanced salt solution and replenished with HDMEC media. Thirty-two hours after transfection, control transfectants were left untreated (media change) and test transfectants received either 500 U/mL TNFa or 500 U/mL 1L-la for 16 hours. Cells were then harvested and lysates were prepared. CAT expression was determined by acetylation of I4C-labeled chloramphenicol (Amersham Corp, Arlington Heights, IL) and analyzed by thin-layer chromatography followed by scintillation counting. Protein concentration of lysates was determined using the DC Protein Standard Assay (Bio-Rad, Hercules, CA). As an internal control for transfection efficiency, 3 pg of a pSV-P-galactosidase control vector (Promega) were cotransfected in each set of experiments. P-Galactosidase activity was determined by enzyme-linked immunosorbent assay using the Promega Enzyme Assay System. Amounts of lysates used for CAT activity analysis were normalized for 0-galactosidase activity. Transfection efficiency among different reporter gene plasmids varied between 9% and 138%. Variability in transfection efficiency among different experimental procedures for a given transfected construct ranged between 4% and 16%.
Preparation of nuclear extracts and gel mobility-shift analysis.
Confluent EC cultures were treated with either TNFa (500 UlmL) or 1L-la (500 U/mL) for 4 hours. In vitro-translated nuclear proteins were extracted as previously described by Dignam et sized by annealing an oligonucleotide complementary to the 3' end of the sequence listed above (underlined, 5"CATAGGATCTCG-AGC-3') and by extending the second strand with Klenow fragment. 50 pCi ["PIdCTP, unlabeled dATP, dGTP. and dTTP followed by addition of unlabeled dCTP to ensure completion of the second strand. All oligonucleotides were synthesized by the Emory University Microchemistry Facility. Unincorporated nucleotides were removed by column chromatography over G-25 Sephadex columns (Boehringer Mannheim Corp. Indianapolis, IN). Cold doublestranded DNA was made identically, except that unlabeled dCTP was substituted for labeled dCTP. The DNA binding reaction was performed for 30 minutes at room temperature in a volume of 20 p L containing 2 to 4 pg nuclear protein extract, 2.5 m g h L fetal bovine albumin, 105 cpm "P-labeled probe (= 1 ng), 0.1 mg/mL poly(d1:dC). and 5 pL 4X binding buffer Stntisrics. For statistical analysis, Student's 1-tests were used. P values more than . OS were not considered significant.
RESULTS
A -288-bp VCAM-I CAT construct is equallv activated by T N F a and IL-la i n HUVEC and HDMEC. To determine whether the two adjacent NF-KB sites of the human VCAM-1 promoter account for differential VCAM-I regulation, a -288-bp VCAM-I CAT construct, containing the tandem NF-KB sites, was transfected into either HUVEC or HDMEC. Subsequently, respective CAT activities in response to T N F a and IL-la were analyzed (Fig 1 ) . Whereas only minor basal C A T expression was appreciated in untreated EC, the C A T conversion as a result of promoter activation was markedly increased by TNFa in both HUVEC and HDMEC. Comparable transcriptional activation was also recognized in response to IL-la. Significantly, no discernible differences in activation of the -288-bp construct were seen in HUVEC versus HDMEC. These data thus sug- gest that within the first 288 basepairs of the VCAM-I promoter, which contain the critical NF-KB motifs necessary for cytokine responsiveness, no regions are present that can account for the differential VCAM-I expression seen with IL-la. To further solidify this conclusion, we next performed electrophoretic mobility-shift assays.
TNFa and IL-la induce comparable NF-KB element-dependent binding in HDMEC. To examine interactions of cytokine-induced nuclear proteins with the NF-KB DNA sequence of the VCAM-1 promoter, we performed electrophoretic mobility-shift assays using nuclear extracts of either untreated, TNFa-treated, or IL-la-treated HDMEC and a radiolabeled double-stranded DNA probe corresponding to the exact VCAM-I tandem NF-KB sites (Fig 2) . The first two lanes demonstrate complexes formed with lysates of untreated cells. These bands are nonspecific, since they are also seen in the presence of excess cold relevant DNA probe. However, with both TNFa-and IL-la treatment, intense specific complexes are formed. Specificity was confirmed by exclusive competition with excess cold relevant DNA. but not with irrelevant DNA. These specific complexes, induced by both TNFa and IL-la, were supershifted with antibodies directed against the two components of the classic NF-KB complex, RelA (p65) and NFKB I (p50). Specifically, the upper complex (band A) was supershifted by both antiRelA and anti-NFKBI, whereas the lower complex (band B) was only recognized by anti-NFKB 1. These data suggest that comparable nuclear protein complexes occupied NF-KB motifs of the VCAM-I promoter in TNFa-and IL-latreated HDMEC, providing additional evidence that neither activation nor DNA binding of NF-KB are responsible for the differential VCAM-I regulation in EC.
A regulation in HUVEC versus HDMEC, we next determined whether elements further upstream in the VCAM-l promoter are responsible for the lack of IL-la-mediated VCAM-1 expression in HDMEC. We therefore analyzed CAT expression in response to TNFa and IL-la with a series of larger VCAM-1 -based reporter constructs transfected into HU-VEC and HDMEC. One of the constructs used in these studies, a -933-bp VCAM-l CAT construct, clearly demonstrated differential responsiveness to IL-la (Fig 3) . When transfected into HUVEC, increased CAT expression occurred with both TNFa and IL-la treatment. However, in HDMEC, while TNFa responsiveness was retained, IL-la induction was significantly reduced (*P < .001, Student's t-test). An equivalent pattern of cytokine response was also observed with longer VCAM-I promoter constructs (eg, -1151/+20 VCAM-l CAT construct; data not shown). These findings support a transcriptional model for a HDMEC-specific attenuation of VCAM-1 promoter activation in response to IL-la, but not TNFa.
Transcriptional regulation of the VCAM-I promoter by selective expression of NF-KB subunits is unaffected by the presence of different upstream portions of the regulatory region. Since both TNFa and IL-la appear to activate NF-KB via a similar signaling pathway," we next explored whether the differential VCAM-l gene transcription in response to TNFa and IL-la in HDMEC depends on additional cytokine-specific mechanisms. To bypass cytokineinduced NF-KB activation and to selectively study the effect of NF-KB trans-acting proteins with regard to the presence of different VCAM-l regulatory regions, we cotransfected expression vectors encoding for the NF-KB subunits, NFKB 1 (p50) and RelA (~65). as well as the inhibitor protein I K B~, in concert with either the -288-bp or -933-bp VCAM-1 CAT reporter construct (Fig 4) . Cotransfection of RelA expression vector markedly activated both the -288-bp and -933-bp VCAM-l promoter constructs, whereas expression of NFKBl restricted promoter activity below baseline expression. In addition, coexpression of RelA with either NFKB 1 or I K B~ negatively regulated transcriptional activation in comparison to cotransfection of RelA expression vector alone. Although the NF-KB motif in the VCAM-l promoter allows binding to both RelA and NFKB 1 (Fig 2) , only RelA optimally activated the VCAM-1 promoter regardless of the presence of different VCAM-l promoter upstream regions. These findings, revealing comparable patterns of gene activation with both reporter constructs, thus support the notion that specific cytokine-dependent mechanisms, which do not involve NF-KB transcription factors, are responsible for the differential VCAM-l transcription in HDMEC. Taken together, observations from both the CAT assays and electrophoretic mobility-shift assay experiments, as well as the cotransfection studies, therefore demonstrate that the NF-KB sites of the VCAM-l promoter can not account for the differential VCAM-l regulation by IL-la in HUVEC versus HDMEC.
Regulatory elements between -933 and -770 bp appear to be responsible for the differential VCAM-I promoter activation by IL-la. To further localize the region responsible for this tissue-and cytokine-specific attenuation, CAT activity of a sequential series of VCAM-1-based reporter constructs was analyzed (Fig 5) . Both the -629-bp and -770-bp VCAM-I CAT construct displayed comparable responsiveness to both TNFa and L-la. Although promoter activation of the -770-bp, -629-bp, and -288-bp vector by IL-la was consistently lower than that observed in TNFatreated EC, this difference was not statistically significant. These data thus indicate that the region responsible for differential VCAM-l promoter activation by IL-la is localized between positions -933 bp and -770 bp.
A -933/-700-bp VCAM-I promoter sequence inhibits ILla-mediated activation of a heterologous cytokine response element andpromoter in HDMEC. To study the hypothesis of an IL-la-mediated transcriptional repression, we modified a heterologous cytokine response element and promoter construct by inserting the putative inhibitory VCAM-l promoter segment (-933/-700 bp) and studied the transcriptional activation in response to TNFa and IL-la of this hybrid gene construct (ICAM-NFKB+VCAM-R~~ TK CAT) in comparison to the cytokine-induced expression of a construct lacking the VCAM-l promoter sequence (ICAM-NFKB TK CAT; Fig 6) . The region of the ICAM-1 gene used has been demonstrated to contain a variant NF-KB binding site that mediates enhanced transcription in response to TNFa, IL-l, and phorbol myristate acetate.20.2"26 Whe n the ICAM-NFKB TK CAT plasmid was transfected into HDMEC, increased CAT expression was found in a similar fashion with both TNFa and IL-la treatment. However, when the ICAM-NFKB+VCAM-Rep TK CAT hybrid construct con- taining the putative VCAM-I repressor region was transfected, IL-la induction was virtually inhibited and
TNFa responsiveness was retained (*P < .005, Student's ftest). These data suggest that elements within the -9331 -700-bp fragment of the VCAM-I promoter inhibit IL-lamediated transcriptional activation of a heterologous IL-laresponsive element and promoter in HDMEC, supporting the concept of a cytokine-specific repressor in the S'-regulatory region of the VCAM-I gene.
DISCUSSION
Based on previous observations demonstrating a differential VCAM-I induction by TNFa and IL-la in HUVEC GlLLE ET AL versus HDMEC,"' we hypothesized that these primary EC types can serve as a model to study transcriptional regulation in a tissue-and cytokine-specific manner. As an important step in determining molecular mechanisms that dictate differential VCAM-I transcription in a cell-and cytokine-selective fashion, we here report a significant HDMEC-specific reduction of VCAM-I gene transcription in response to ILla, but not TNFa.
The observations of differential VCAM-I expression by TNFa and IL-la on HDMEC are consistent with findings of VCAM-I regulation in vascular smooth muscle cells and correlate with in vivo data obtained from different cutaneous inflammatory processes. In immunohistochemical studies, in vivo injection of TNFa into the skin of baboons was followed by marked VCAM-I expression on EC after 6 hours, and was associated with accumulation of mononuclear leukocytes in the dermis." However, IL-I injection into human skin resulted only in a modest induction of VCAM-I on dermal EC, which was in sharp contrast to the robust upregulation of E-selectin.2x Comparable observations of cytokineinduced VCAM-I regulation have been recently reported on human vascular smooth muscle Whereas TNFa led to marked VCAM-I expression at both the cell-surface and mRNA level, IL-ID failed to induce VCAM-I in these cells. As we have previously demonstrated with HDMEC, this difference in VCAM-l regulation was not due to the lack of IL-I responsiveness in vascular smooth muscle cells, since IL-I resulted in expression of ICAM-I in a time-and concentration-dependent manner.
Characterization of the VCAM-I promoter has revealed two adjacent NF-KB binding sites within the first 77 basepairs upstream from the transcription start site,"." which are both required for transcriptional activation of the VCAM-I gene in response to TNFa.'" These two tandem NF-KBlike binding sites are not only involved in cytokine-induced transcription, but have also been implicated in cell typespecific VCAM-I gene regulation.13.1h." Therefore, we hypothesized that NF-KB may play a role in the differential VCAM-I expression in response to TNFa and IL-a in HU-VEC versus HDMEC.
Transfection studies with a basic VCAM-I -based reporter construct containing the tandem NF-KB motifs revealed comparable activation by both TNFa and IL-la in HUVEC and HDMEC. In addition, DNA binding assays suggested that the NF-KB elements are occupied by equivalent NF-KB complexes after stimulation with TNFa and IL-1 a, providing further evidence that NF-KB transcription factors are not involved in the HDMEC-specific lack of IL-I a-induced VCAM-1 expression. However, transcriptional activation studies with a larger -933-bp VCAM-I CAT construct showed a differential responsiveness to IL-la. The observations demonstrated a significant HDMEC-specific attenuation of VCAM-I gene transcription in response to ILla but not to TNFa, leading to the hypothesis of an upstream regulatory element that functions as an IL-la-mediated repressor of VCAM-I gene expression in HDMEC. The concept of a transcriptional repressor was tested in the context of a heterologous cytokine response element and promoter. These studies showed that a -933/-700-bp fragment of the VCAM-I promoter is sufficient to inhibit IL-la-induced
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transcriptional activation of a heterologous IL-la response element and promoter in HDMEC. Conceivably, HDMEC may constitutively express an inhibitory or repressor protein that selectively binds to this region. In this model, TNFa is able to overcome this inhibition, but IL-la may fail to do so. Alternatively, IL-la could specifically induce a protein in HDMEC that inhibits VCAM-1 gene transcription via interaction with elements of this upstream VCAM-l regulatory region.
In conclusion, we demonstrate that the HDMEC-specific lack of IL-la responsiveness is regulated, at least in part, at the level of gene transcription. Despite strong evidence implicating two closely linked NF-KB elements of the VCAM-1 promoter in cell-specific VCAM-1 transcription, our studies do not reveal a critical role of NF-KB in this cytokine-and EC-specific VCAM-l regulation. Rather, an upstream regulatory element of the VCAM-1 promoter appears to function as an IL-la-mediated transcriptional repressor within HDMEC. These studies further solidify the important biologic differences that can be seen among EC from different organ sources. Clarification of these differences is critical when using EC as models and investigative tools in studies of vascular biologic and pathophysiologic processes.
